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Cardiovascular disease (CVD), the leading cause of death
and disability worldwide, imposes huge healthcare costs
to society and significant burdens to patients. It is esti-
mated that 18 million deaths occurred from CVD annu-
ally worldwide [1]. Over three quarters of CVD deaths
take place in low- and middle-income countries includ-
ing Iran. Therefore, developing and implementing public
health strategies is necessary for primary and secondary
prevention of CVD [2]. Many of these deaths may be
prevented with use of approved medications. Guidelines
strongly recommend the use of medicines including as-
pirin, statins, beta blockers, and angiotensin-converting
enzyme (ACE) inhibitors or angiotensin-II receptors
blockers (ARBs) for prevention of CVD risk factors in-
cluding hypertension, dyslipidemia and thrombosis [3].
Nowadays fixed-dose combination therapy is recom-
mended. However, the possible superior clinical effect of
polypill compared to statins alone for primary preven-
tion of CVD in intermediate risk population has not
been investigated yet.
According to the importance of dyslipidemia, current
guidelines recommend statins in the primary prevention
of CVD based on predicted cardiovascular risk approach.
The American College of Cardiology and American
Heart Association (ACC/AHA) statin guidelines recom-
mend high and moderate-high intensity statin therapy
for all adults with low density lipoprotein-cholesterol
(LDL-C) equal or greater than 190 mg/dl and risk of
CVD ≥7.5% over 10 years, respectively [4]. Moreover,
ACC/AHA recommends moderate-intensity therapy for
adults without diabetes mellitus, aged 40–75 years with
5–7.5% risk of CVD over 10 years [5]. In this regard,
Khalili et al. showed that the 2013 ACC/AHA guideline
on statin therapy could be useful for both moderate and
intensive treatment of hypercholesterolemia and preven-
tion of CVD events in Iranian population [6]. However,
Thanassoulis et al. (2016) revealed that an individualized
statin benefit approach based on predicted absolute risk
reduction over 10 years in comparison with the 10-year
risk-based approach could better identify eligible lower-
risk individuals who meaningfully benefit from statin
treatment [7]. In spite of probable statins adverse effects
like muscle pain and increasing serum blood sugar,
meta-analysis of randomized trials which evaluated the
effect of statin on primary prevention of CVD documented
that 1 mmol per liter reduction of LDL-C with statin was
associated with 25% lower risk of CVD events [8].
Yusuf et al. (2016) recently published the primary results
of the Heart Outcomes Prevention Evaluation (HOPE)-3
study, a multicenter, international, double-blind, random-
ized, placebo-controlled trial [9–11]. This study was con-
ducted on 12705 intermediate-risk person of various
ethnic backgrounds on six continents and 21 countries
who did not have CVD with no specific lipid or blood
pressure levels for entry. Participants were randomly
assigned to rosuvastatin group at a dose of 10 mg per day
or placebo and were also randomly assigned to candesar-
tan (16 mg per day) plus hydrochlorothiazide (12.5 mg per
day) or placebo for a median follow-up of 5.6 years. They
revealed that treatment with rosuvastatin resulted in a
24% lower risk of cardiovascular events compared to pla-
cebo. However, blood-pressure lowering treatment did not
significantly reduce the risk of cardiovascular events in
this intermediate-risk population without cardiovascular
disease. Moreover, the comparison of the combined inter-
vention effects with placebo showed no more benefit than
rosuvastatin alone [9–11]. The results of HOPE-3 study
provide the evidence in support of statin use for primary
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prevention of CVD. Moreover, Karmali et al. (2016)
searched the systematic reviews which evaluated the
effect of aspirin, blood pressure-lowering therapy, or
statins on cardiovascular events in individuals without
prevalent CVD. They showed that aspirin, statins and
BP-lowering therapy individually reduced the risk for
CVD compared with placebo by 10%, 25% and 16%
respectively [3].
Low adherence to prescribed treatments is a major
barrier in prevention of CVD. Poor long-term adherence
to prescribed medications could be related to social, cul-
tural, psychological and economic factors. Moreover, low
availability and affordability of medicines are associated
with low adherence. Reducing the number of medica-
tions is an approach to increase patient adherence which
may be achieved by fixed-dose combination therapy
such as polypill. Most of the tested polypills include a
statin, an aspirin, a beta blocker, a diuretic or a calcium
channel blocker, an ACE inhibitor or an ARB. Chrysant
and Chrysant (2016) in five studies including 1142 high-
risk participants showed that polypill was usefull for the
primary prevention of CVD by decreasing blood pressure
and LDL-C concentration [12]. Sepanlou et al. (2012) con-
ducted a meta-analysis to estimate the effect of polypill on
primary prevention of ischemic heart disease and stroke
in Iranians aged 55 years or older. They revealed that
using polypill may reduce ischemic heart disease and
stroke deaths by 30% and 53%, respectively [13].
Although a randomized controlled trial is conducting
to evaluate the effect of polypill on prevention of CVD
in Iranian participants, now there is no evidence of the
efficacy, safety and cost-effectiveness of polypill ap-
proach for primary prevention of CVD in Iran. There-
fore, it seems that health providers should not hurry in
polypill recommendation in public health approach. The
cost-effectiveness, risk-assessment and acceptability of
polypill treatment remain to be investigated. Conducting
a randomized clinical trial is recommended to compare
the effects of statins with polypill on primary prevention
of CVD in Iranian population. Given that generic statins
are widely available and affordable in Iran, it seems
that it could be an appropriate candidate for prescrib-
ing in intermediate-risk population for primary pre-
vention of CVD.
In conclusion, it seems that only patients receiving
several drugs with a history of poor adherence to treat-
ments could be good candidates for administration of
fixed dose polypill. In other cases, regarding the cost, ef-
ficacy and availability of statins, the moderate-intensity
therapy of this medication could be applied in primary
care in intermediate-risk individuals. Totally, for coun-
tries that polypill development and preparation is not
cost-effective, it seems that statins alone is a good choice
for primary prevention of CVD.
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